Evidence map›Paper›PMID 41469159›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Construction and Evaluation of Guanylyl Cyclase C-Specific Antibody for Noninvasive Diagnosis and Targeted Therapy of Colorectal Cancer.

Zhuona Rong, Hongjin Liu, Xia Teng, Lin Chen, Yanlun Gu, Bingqi Dong, Xiaojiang Duan, Xin Wang, Xiaocong Pang

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhuona RongDepartment of Pharmacy, Peking University First Hospital, Xicheng District, Beijing, China.
Hongjin LiuDepartment of Gastrointestinal Surgery, Peking University First Hospital, Xicheng District, Beijing, China.
Xia TengState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Haidian District, Beijing, China.
Lin ChenDepartment of Pharmacy, Peking University First Hospital, Xicheng District, Beijing, China.
Yanlun GuInstitute of Clinical Pharmacology, Peking University, Haidian District, Beijing, China; and.
Bingqi DongDepartment of Gastrointestinal Surgery, Peking University First Hospital, Xicheng District, Beijing, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, Xicheng District, Beijing, China duanxj2018@bjmu.edu.cn wangxin_guo@126.com pangxiaocong1227@163.com.
Xin WangDepartment of Gastrointestinal Surgery, Peking University First Hospital, Xicheng District, Beijing, China; duanxj2018@bjmu.edu.cn wangxin_guo@126.com pangxiaocong1227@163.com.
Xiaocong PangDepartment of Pharmacy, Peking University First Hospital, Xicheng District, Beijing, China; duanxj2018@bjmu.edu.cn wangxin_guo@126.com pangxiaocong1227@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains the leading cause of cancer mortality worldwide despite therapeutic advances. Guanylyl cyclase C (GUCY2C), an intestinal epithelial receptor, is emerging as a promising diagnostic and therapeutic target for CRC. Thus, we are interested in developing a monoclonal antibody probe targeting GUCY2C for both in vitro and in vivo diagnosis and treatment of CRC.

Indexed as

Antibodies, MonoclonalAntibody SpecificityColorectal NeoplasmsMolecular Targeted TherapyReceptors, Guanylate Cyclase-CoupledReceptors, PeptideAnimalsCell Line, TumorFemaleHumansMicePositron-Emission TomographyReceptors, EnterotoxinAntibodies, MonoclonalGUCY2C protein, humanReceptors, EnterotoxinReceptors, Guanylate Cyclase-CoupledReceptors, Peptideantibody-based PETcolorectal cancerguanylyl cyclase Cnear-infrared fluorescent IIradioimmunotherapy

Identifiers

PMID41469159
PMCPMC12955545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.